William Blair Estimates 10x Genomics Q3 Earnings

10x Genomics, Inc. (NASDAQ:TXG) – Research analysts at William Blair issued their Q3 2025 earnings per share (EPS) estimates for 10x Genomics in a research report issued to clients and investors on Thursday, February 13th. William Blair analyst M. Larew anticipates that the company will earn ($0.33) per share for the quarter. The consensus estimate for 10x Genomics’ current full-year earnings is ($1.43) per share. William Blair also issued estimates for 10x Genomics’ Q4 2025 earnings at ($0.32) EPS, Q1 2026 earnings at ($0.32) EPS, Q2 2026 earnings at ($0.23) EPS, FY2026 earnings at ($1.02) EPS and FY2026 earnings at ($1.02) EPS.

A number of other research firms also recently commented on TXG. The Goldman Sachs Group cut their price objective on shares of 10x Genomics from $16.00 to $14.00 and set a “sell” rating for the company in a report on Wednesday, October 30th. UBS Group cut their price target on 10x Genomics from $20.00 to $14.00 and set a “neutral” rating for the company in a report on Thursday. Weiss Ratings reissued a “sell (e+)” rating on shares of 10x Genomics in a research note on Saturday, February 1st. Leerink Partnrs downgraded 10x Genomics from a “strong-buy” rating to a “hold” rating in a research note on Thursday. Finally, Leerink Partners cut shares of 10x Genomics from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $25.00 to $12.00 in a research report on Thursday. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and seven have given a buy rating to the company. According to MarketBeat, 10x Genomics presently has an average rating of “Hold” and an average price target of $20.57.

10x Genomics Stock Up 3.1 %

Shares of NASDAQ TXG opened at $12.31 on Monday. The stock has a market capitalization of $1.49 billion, a price-to-earnings ratio of -8.05 and a beta of 1.85. 10x Genomics has a 52 week low of $10.80 and a 52 week high of $51.22. The firm has a 50-day simple moving average of $14.68 and a 200-day simple moving average of $17.33.

10x Genomics (NASDAQ:TXG) last posted its quarterly earnings data on Wednesday, February 12th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.08). 10x Genomics had a negative net margin of 28.93% and a negative return on equity of 25.07%.

Institutional Investors Weigh In On 10x Genomics

A number of institutional investors have recently modified their holdings of TXG. Signaturefd LLC grew its holdings in shares of 10x Genomics by 424.6% in the fourth quarter. Signaturefd LLC now owns 1,794 shares of the company’s stock valued at $26,000 after purchasing an additional 1,452 shares in the last quarter. Capital Performance Advisors LLP acquired a new position in shares of 10x Genomics in the third quarter worth $35,000. Blue Trust Inc. increased its position in shares of 10x Genomics by 136.5% during the third quarter. Blue Trust Inc. now owns 1,776 shares of the company’s stock worth $40,000 after acquiring an additional 1,025 shares during the period. Sound Income Strategies LLC raised its stake in shares of 10x Genomics by 65.2% in the fourth quarter. Sound Income Strategies LLC now owns 3,370 shares of the company’s stock valued at $48,000 after acquiring an additional 1,330 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of 10x Genomics in the fourth quarter valued at $52,000. 84.68% of the stock is owned by institutional investors and hedge funds.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.